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Abstract: Lanthanum carbonate is an efficacious noncalcium, nonresin phosphate-binder that 
is being increasingly used in chronic kidney disease stage 5 (CKD-5) dialysis patients. Available 
evidence has indicated that QT interval changes correlate with mortality in healthy subjects and 
in dialysis patients. Experimental studies have suggested the possibility that lanthanum carbonate 
may produce prolongation of the QT interval. This is not accepted by other authors. There is 
no data confirming this in prospective clinical studies. The goal of this study was to verify the 
effect of lanthanum carbonate on the QT interval of the electrocardiogram (EKG) tracing.
Material and methods: We studied 25 hemodialyzed patients. After a six-month run-in 
period, with aluminum-hydroxide, lanthanum carbonate was administered at increasing doses: 
500 mg twice a day for week 1; 750 mg, twice daily during week 2; 1000 mg twice daily   during 
week 3; and 1000 mg three times daily during week 4. EKGs were recorded on patients prior to 
and 3 hours following each dialysis treatment. Assessments were made of differences in body 
weight; systolic blood pressure; diastolic blood pressure; length of PR and QRS complex; heart 
rate; QT; QT-c; QT-d; and axis of wave P, QRS complex and T using lanthanum carbonate at 
increasing doses.
Results: QT-c is before dialysis session during run-in 431 ± 20 msec with variation by -9 to + 1 
msec (P = not significant [NS]) during lanthanum use; and 437 ± 25 msec after dialysis session 
with variation by -6 to -1 msec (P = NS) during lanthanum use. Any difference was observed 
during study among before and after dialysis session in QT-c (difference by 0.09 to 3.2%) 
(P = NS); and QT-d (difference by 8.6 to 9.1%) (P = NS).
Conclusion: Our study shows that lanthanum carbonate administration, at increasing doses, did 
not modify the EKG parameters. This effect is observed both in predialysis and in postdialysis 
recordings. Further studies are necessary with more prolonged observations.
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Introduction
As documented by the United States Renal Data System, congestive heart failure and 
sudden death are the most frequent causes of cardiovascular death in chronic kidney 
disease stage 5 (CKD-5), followed by acute myocardial infarction, stroke, and peripheral 
arterial disease (http://www.usrds.org/2006/ref/H_morte_06.pdf). Different factors have 
been investigated to explain the pathogenesis of cardiac arrhythmias that lead to sudden 
cardiac death (SCD) in hemodialysis.1 In particular, coronary artery disease (CAD), 
arterial hypertension, congestive heart failure, autonomic neuropathy and uremic car-
diomyopathies might induce a significant cardiac remodeling that affects number and 
functionality of cardiac ion channels.1 Specifically, it has been postulated that patients 
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the potassium channels that might lead to a reduction of the 
“cardiac repolarization reserve”.1 In addition, several drugs and 
the acute changes in levels of serum calcium and potassium that 
occur during a dialysis session further exacerbate the risk of 
cardiac arrhythmias as documented by changes in the QT tract 
on electrocardiogram (EKG) (http://www.qtdrugs.org).2–5
Some experimental studies6,7 have suggested the possibil-
ity that lanthanum carbonate may produce extension of QT 
intervals. This is not accepted by other authors.8,9 Lanthanum 
carbonate is an efficacious noncalcium, nonresin phosphate-
binder increasingly used in CKD-5   dialysis-patients; and there 
is no data confirming this in prospective clinical studies.
The goal of this study was to verify the effect of lantha-
num carbonate on QT interval changes on EKG recordings 
in patients with CKD-5 undergoing hemodialysis.
Materials and methods
A total of 25 CKD-5 hemodialysis patients participated this 
four-week study. Following a six-month run-in period with 
aluminum-hydroxide, patients received lanthanum carbonate. 
Aluminum hydroxide is not a preferred phosphate-binder in 
our dialysis center. It was used in this study protocol because it 
is known not to influence QT interval changes. The   temporary 
use of aluminum hydroxide did not cause dementia or other 
neurological disease in the patients. All patients introduced 
the lanthanum carbonate dose as prescribed, and this is shown 
by the blood phosphorus and confirmed by radiographies of 
the abdomen that showed the presence of lanthanum.
Lanthanum carbonate was administered at a dose 500 mg 
twice daily during week 1; 750 mg twice daily during week 2; 
1000 mg twice a day during week 3; and 1000 mg three times 
daily during week 4. The dose of lanthanum carbonate was 
increased regardless of serum phosphate in order to investigate 
the influence of the drug and if there was a dose response.
EKGs were run on each patient before and three-hours 
after each dialysis session. The EKG reader was blinded to 
the lanthanum carbonate dose.
Patients were included if they were adults over the age 
of 18 years on hemodialysis treatment and currently on 
phosphate-binders. Exclusion criteria included concomitant 
acute illness or history of cardiac arrhythmia, liver dysfunc-
tion and   hypothyroidism, and use of drugs that prolong the 
QT interval. Written informed consent was obtained from all 
participants before study-related procedures were performed 
and after approval from each institutional Ethical Review 
Board. All procedures involved in the study were conducted 
in adherence to the Declaration of Helsinki, Ethical Principles 
for Medical Research Involving Human Subjects.
Investigators were instructed to control blood pressure 
(#130/80 mmHg), anemia (hemoglobin [Hb] . 11 g/dL, 
transferrin saturation [TSAT] . 20%), acidosis (bicar-
bonate [HCO3] between 20–24 mmol/L), diabetes (gly-
cated hemoglobin [HbA1c] , 7.0%), dyslispidemia (total 
cholesterol ,200 mg/dL; low-density lipoprotein [LDL] 
cholesterol ,100 mg/dL; triglycerides , 180 mg/dL), and 
parameters of bone mineral metabolism (serum phosphorous, 
calcium, and intact parathyroid hormone [iPTH] between 
2.5–5.0 mg/dL; 8.0–9.9 mg/dL, and 150–300 pg/mL respec-
tively) according to current guidelines.
Routine biochemical laboratory measurements were 
obtai  ned at baseline and at six months intervals. All blood 
samples were taken before the midweek dialysis session 
and after 12 hours fasting. Serum parameters of mineral 
metabolism, electrolytes, inflammation, anemia, liver func-
tion, and dialysis adequacy were performed by the facilities’ 
usual laboratories.
The bath of dialysis contained calcium at dose of 
1.25 mmol/L and potassium at dose of 3 mmol/L.
QT interval and QT dispersion was assessed on a 
12-channel recorder (Esaote-Biomedicals, Genova, Italy) at a 
paper speed and gain of 25 mm/sec and 10 mm/mV , respec-
tively.10 The QT interval was measured by one single observer 
as the distance between the beginning of the QRS complex 
and the end of the T wave. Moreover, each QT interval was 
also corrected for the heart rate using the Bazett’s formula 
(QTc = QT/RR). The difference between the   maximum QTc 
and the minimum QTc was also calculated and represents 
the corrected QT interval dispersion (QTcd). The P, QRS, 
and T axes were measured. The electrocardiograms were 
effected before and three hours after the second weekly 
dialysis session.
Statistical methods
Demographic, clinical and laboratory characteristics were 
collected at enrollment and at the end of study.
Data are expressed as mean ± standard deviation unless 
otherwise specified. A t-test was used to compare the run-
in period and the end of the study. Analysis of variance 
(ANOVA) were used to verify the variations of QT-c and 
QT-d, and axis of P wave, QRS complex, and T wave during 
the lanthanum administration. A P-value of less than 0.05 
was considered statistically significant.
Results
Demographic, clinical and laboratory characteristics 
of patients are summarized in Table 1. Patients were Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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66.2 ± 8.5 years of age, 68% were males, 44% had cerebro-
cardio-vascular disease, 84% with hypertension, and 32% 
were diabetic. Serum phosphorus dropped by the end of the 
study (P , 0.001); and LDL-cholesterol increased following 
lanthanum carbonate use (P , 0.018). Table 2 shows the 
data weekly collected in the predialysis session during run-in 
and following the study: any difference there is regarding 
BW;SBP; DBP; length of PR and QRS complex; heart rate; 
QT; QT-c; QT-d; and axis of wave P, QRS complex, and T 
in patients using lanthanum carbonate at increased doses.
Table 1 Demographic and clinical characteristic of the study 
cohort 
  Start of study End of study
number 25
Males (%) 68
Age (years) 66.2 ± 8.5
AsCVD (%) 44
hypertension (%) 84
Diabetes (%) 32
sBP (mmhg) 145 ± 25 155 ± 27 ns
DBP (mmhg) 65 ± 15 68 ± 9 ns
Phosphorous (mg/dL) 4.1 ± 1.1 3.0 ± 9 0.0001
Calcium (mg/dL) 8.5 ± 0.3 8.2 ± 0.2 ns
hemoglobin (g/dL) 11.2 ± 1.0 11.6 ± 1.6 ns
Intact-PTh (pg/mmoL) 499 ± 443 491 ± 424 ns
Albumin (g/dL) 3.8 ± 0.5 3.8 ± 0.4 ns
LDL-cholesterol (mg/dL) 104 ± 26 127 ± 39 0.018
CrP (mg/dL)  7.5 ± 9.5 8.8 ± 7.6 ns
QTc (msec) 431 ± 20 424 ± 24 ns
QTd (msec) 33 ± 12 34 ± 11 ns
Abbreviations:  AsCVD,  cerebrovascular  disease;  peripheral  vascular  disease; 
angina  pectoris;  history  of  myocardial  infarction;  aortic  aneurysm;  history  of 
percutaneous coronary angioplasty without stenting; CrP, C-reactive protein; DBP, 
diastolic blood pressure; LDL, low-density lipoprotein; NS, not significant; PTH, 
parathyroid hormone; QTc, corrected QT interval; QTd, corrected QT dispersion; 
sBP, systolic blood pressure.
Table 2 The eKg data following study in predialysis
Start First week Second week Third week Fourth week P
BW (kg) 78.4 ± 20.4 79.0 ± 20.6 78.4 ± 21 78.7 ± 20 78.6 ± 22 ns
sBP (mmhg) 145 ± 25 144 ± 30 155 ± 25 157 ± 25 155 ± 27 ns
DBP (mmhg) 65 ± 15 66 ± 20 65 ± 19 69 ± 17 68 ± 19 ns
Pr length (msec) 189 ± 9 183 ± 11 186 ± 12 186 ± 10 180 ± 14 ns
Qrs length (msec) 87 ± 8 81 ± 19 88 ± 7 86 ± 7 85 ± 8 ns
heart rate (b/min) 66 ± 7 69 ± 8 65 ± 9 66 ± 7 66 ± 9 ns
QT (msec) 412.8 ± 33.7 406 ± 45 408 ± 30 407 ± 44 409 ± 43 ns
QT-c (msec) 43.1 ± 20 432 ± 33 422 ± 24 425 ± 24 424 ± 25 ns
QT-d (msec) 33 ± 12 35 ± 14 34 ± 13 33 ± 16 34 ± 11 ns
P axis° 35 ± 14 32 ± 23 23 ± 22 36 ± 12 35 ± 11 ns
Qrs axis° 19 ± 27 16 ± 29 19 ± 21 12 ± 20 12 ± 21 ns
T axis° 56 ± 51 64 ± 67 54 ± 59 71 ± 66 71 ± 66 ns
Abbreviations: BW, body weight; DBP, diastolic blood pressure; NS, not significant; QTc, corrected QT interval; QTd, corrected QT dispersion; 
sBP, systolic blood pressure.
Similarly, Table 3 shows the data collected weekly in 
postdialysis sessions: showing any difference there is regard-
ing BW; SBP; DBP; length of PR and QRS complex; heart 
rate; QT; QT-c; QT-d; and axis of wave P, QRS complex, 
and T using lanthanum carbonate at increase doses.
Particularly, QT-c was generated prior to the dialysis 
session during run-in 431 ± 20 msec with variation by 
-9 to +1 msec (P = not significant [NS]) during lanthanum 
carbonate use; and 437 ± 25 msec after the dialysis session 
with a variation by -6 to -1 msec (P = NS) during lanthanum 
carbonate use. Figure 1 shows the differences during the 
study before and after the dialysis session in QT-c (differ-
ence by 0.09 to 3.2%) (P = NS); and QT-d (difference by 
8.6 to 9.1%) (P = NS).
Discussion
Previous papers have indicated that the QT interval correlates 
with mortality in healthy subjects.11–15 Similar observations 
have been shown in dialysis patients.16,17 Several papers 
have demonstrated that dialysis treatment increases the QT 
interval.1–5 Specifically, it has been postulated that patients 
undergoing hemodialysis might experience a progressive 
diminution and inhibition of the potassium channels that might 
lead to a reduction of the “cardiac repolarization reserve”.1 
Nonetheless, several routinely-used drugs can increase the 
QT interval, such as cisapride,18,19 erythromycin,20 antip-
sychotic drugs,21 sotalol and quinidine,22 ibuprofen,23 and 
aliskerin.24 Patients on dialysis treatment must use phosphate-
binders. Lanthanum carbonate is an oral noncalcium, nonresin 
phosphate-binder widely used in end-stage renal disease. 
Experimental studies6,7 have suggested the possibility that lan-
thanum carbonate may produce extension of the QT interval. 
This evidence isn’t accepted by other authors.8,9 To date, we Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Table 3 The electrocardiogram data following study in postdialysis
Start First week Second week Third week Fourth week P
BW (kg) 76.4 ± 20.5 73.7 ± 23.6 76.4 ± 20.8 76.3 ± 20.7 76.4 ± 21.2 ns
sBP (mmhg) 148 ± 29 133 ± 37 142 ± 24 147 ± 13 145 ± 27 ns
DBP (mmhg) 71 ± 13 66 ± 22 67 ± 11 73 ± 16 68 ± 19 ns
Pr length (msec) 188 ± 10 184 ± 11 194 ± 20 183 ± 14 187 ± 24 ns
Qrs length (msec) 91 ± 8 89 ± 7 94 ± 11 91 ± 7 92 ± 8 ns
heart rate (b/min) 67 ± 10 68 ± 7 67 ± 11 67 ± 9 66 ± 9 ns
QT (msec) 417 ± 54 407 ± 42 416 ± 52 415 ± 45 409 ± 43 ns
QT-c (msec) 437 ± 25 431 ± 30 436 ± 22 434 ± 20 434 ± 25 ns
QT-d (msec) 36 ± 13 38 ± 15 37 ± 14 36 ± 17 37 ± 13 ns
P axis° 41 ± 12 34 ± 8 39 ± 12 33 ± 10 35 ± 11 ns
Qrs axis° 17 ± 29 16 ± 23 12 ± 25 12 ± 28 12 ± 21 ns
T axis° 50 ± 55 49 ± 56 55 ± 61 62 ± 67 61 ± 66 ns
Abbreviations: BW, body weight; DBP, diastolic blood pressure; NS, not significant; QTc, corrected QT interval; QTd, corrected QT dispersion; 
sBP, systolic blood pressure.
3.5
3
2.5
2
1.5
1
0.5
0
9.5
9
8.5
8
run-in
Q
T
-
c
Q
T
-
d
1 week 2 weeks
QT-c QT-d
3 weeks 4 weeks
Figure 1 The differences during study among before and later dialysis session in QT corrected interval (QT-c) (P = ns); and QT dispersion (QT-d) (P = ns).
have no clinical studies focused on the effects of lanthanum 
carbonate on QT interval changes in dialysis patients.
Our study shows that acute lanthanum carbonate admin-
istration, at increasing doses, does not modify the EKG 
parameters. This effect is observed both in predialysis and in 
postdialysis recordings. It underlines the absence of negative 
effects of lanthanum carbonate on the QT interval in acute 
administration of the drug for a four-week time period with 
increasing doses.
A few limitations have to be taken into account when 
these results are interpreted. Indeed, the relatively small 
sample size and the low reproducibility of the mean QT 
dispersion limit the ability to generalize these findings. 
However, the same patients represent the control group, and 
it isn’t temerity to draw conclusions from only 25 patients 
on dialysis, just considering the enormous diversity of these 
patients. The time of lanthanum carbonate administration was 
short, but the data demonstrated, diversely from preliminary 
pathophysiology data, that acute administration did not 
increase the QT interval.
Furthermore, though prospective, this is not a   randomized 
trial and potential confounders might have influenced our Clinical Pharmacology: Advances and Applications
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results. Therefore further studies are required to confirm that 
the chronic use of lanthanum carbonate does not increase 
the QT interval.
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